ACROBiosystems Innovative Lab Capabilities

In order to make their advanced technology accessible to all of their clients ACROBiosystems now provides lab services.

The new INNOVATION LAB is staffed by scientists who have been working with biological assays for years as part of their assay development range.

MSD-ECL Platform: Broad Range Multiplex Detection via Electrochemiluminescence

ACROBiosystems provides a range of different MSD-based immunoassays that have been shown to improve both sensitivity and dynamic range through the use of electrochemiluminescent labels.

The expert scientists at ACROBiosystems can identify the needs of their clients and assist in the designing of assays that can achieve more than conventional ELISA methods.

How does the Meso Scale Discovery Platform (MSD-ECL) Work?

The MSD-ECL platform uses detection antibodies with electrochemiluminescent labels and detects excitations that occur at electrodes placed at the bottom of each microplate. As electricity is applied to the plate electrodes, the electrochemiluminescent labels are stimulated to emit light.

The intensity of this light is directly proportional to the concentration of the target analyte, thereby providing a quantitative measurement of the analyte. The method can be used for the analysis of whole blood or plasma, cell supernatant or serum.

Image credit: ACRO Biosystems

Ideal MSD Applications: For Multiplexing and Complex Matrices

The MSD-ECL platform provides a high level of flexibility with non-radioactive, stable labels that can easily bind to their targets. Their high flexibility allows these labels to be used for all types of conventional ELISA assays; whether sandwich, competitive, direct or indirect, whilst providing an improved level of sensitivity that allows sample detection at concentrations as low as 0.1 pg/mL.

It has also been shown that MSD assays do not interfere strongly with components such as plasma or serum, making them perfect for use in complex assays. MSD is particularly beneficial because its bridging formats do not show selectivity towards specific antibody subclasses or species.

Examples of samples:

  • Detection of the biomarkers present in whole cell lysates
  • The quantitative analysis of the biomarkers present in plasma and serum samples is possible using assay-specific plasma/serum kits
  • Determination of protein concentrations in tissue culture supernatant
  • Assay development and high-throughput screening of other sample types

MSD-ECL can also be used for the screening of biomarkers, pharmacokinetics (PK), immunogenicity, CAR-T cytotoxicity and pharmacodynamics (PD).

Image credit: ACRO Biosystems

Key MSD-ECL Benefits: High Sensitivity and Broad Dynamic Range

Key benefits of using MSD assays include:

  • A wide dynamic range
  • Highly-sensitive
  • Only requires small sample volumes
  • High signal-to-noise ratio
  • Multiplexing is possible
  • High-throughput

The use of an MSD multi-array assay can provide a greater dynamic range and sensitivity over conventional ELISA assays, and it can also be used for multiplexing. Low sample volumes mean that only small volumes of reagent are required and the method can be carried out quickly and non-destructively to provide highly repeatable assay data.

The use of an electrochemiluminescent label means that the noise-to-signal ratio for measurements can be improved by separation of the signal and the excitation method.

Assays ran using an MSD method are highly economical as there are less readings from below the LLOQ or above the ULOQ, meaning less repeats are required. This also means that more valid data points are collected from one experiment than collected when using other competing methods.

Being able to take fast readings and to carry out several different experiments on the sample at the same time increases experimental throughput, conserves the sample for other experiments and helps to quickly deliver results.

Case Study: Analysis of Proinflammatory Cytokines in Mouse Serum

Samples: Mouse Serum

Analytes: 10 Mouse Cytokines: IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-1β, IFN-γ, TNF-α, KC/GRO

4 Human Cytokines: IFN-γ, IL-1β, Granzyme B, IFasL

Image credit: ACRO Biosystems


  • A large linear range that can be 3 – 4+ log
  • It is possible to analyze up to 10 analytes using the same panel – delivering high time and cost savings
  • The method provides high precision and sensitivity, with reduced interference from free drugs and the matrix

Samples and Turnaround

  • Sample requirements: Serum, plasma and cell culture supernatants are all compatible with the platform. Sample volume is dependent on desired analytes amount (25 ul sample per panel)
  • Turnaround time: MSD operation time largely depends on sample size and the number of analytes. Usually, 5 to 10 business days.
  • What is provided to the clients: Raw data file and data report.

About ACROBiosystems

ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics. The company employs an application oriented development strategy, with a particular focus on product design, quality control and solution based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process.

To respond to coronavirus pandemic, ACROBiosystems has developed SARS-CoV-2 antigens specifically designed and optimized for serological test kits, including Spike-derived antigen S1, RBD and Nucleocapsid protein. Proteins have been supplied to diagnostic companies in large quantity.

Sponsored Content Policy: publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Aug 24, 2020 at 8:00 AM


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ACROBiosystems. (2020, August 24). ACROBiosystems Innovative Lab Capabilities. News-Medical. Retrieved on March 27, 2023 from

  • MLA

    ACROBiosystems. "ACROBiosystems Innovative Lab Capabilities". News-Medical. 27 March 2023. <>.

  • Chicago

    ACROBiosystems. "ACROBiosystems Innovative Lab Capabilities". News-Medical. (accessed March 27, 2023).

  • Harvard

    ACROBiosystems. 2020. ACROBiosystems Innovative Lab Capabilities. News-Medical, viewed 27 March 2023,

Other White Papers by this Supplier